spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  LDL-C 

 HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement
 HSMN NewsFeed - 31 Jul 2019
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Feb 2019
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 4 Feb 2019
CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 12 Sep 2018
FDA to Review Supplemental Biologics License Application for Praluent(R) (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 May 2018
Regeneron and Sanofi to Lower Net Price of Praluent(R) (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 13 Sep 2017
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jan 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Nov 2016
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Nov 2016
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 14 Apr 2016
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jan 2016
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 18 Sep 2015
Mylan Launches One of First Generic Lescol XL(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 26 Jun 2014
Esperion Therapeutics Announces the Appointment of Gilbert S. Omenn, M.D., Ph.D. to Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 6 May 2014
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 13 Jan 2014
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 13 Jan 2014
U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 20 Sep 2013
Teva Announces Exclusive Launch of Generic NIASPAN(R) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 12 Jul 2013
American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) Number
Diagnostics Endocrinology
 HSMN NewsFeed - 24 Jan 2013
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 4 Jan 2013
Tim Mayleben Named President And CEO Of Esperion Therapeutics
Biopharmaceuticlas Personnel
 HSMN NewsFeed - 31 May 2012
New Data Showed LIVALO(R) (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 25 Nov 2011
Amarin Announces Resignation of David Feigal from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Feb 2011
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2011
Atherotech Diagnostics Lab Taps Mize as Vice President of Regulatory Affairs
Diagnostics Personnel
 HSMN NewsFeed - 25 Jan 2011
Respected Gynecologist, Lipidologist Joins Atherotech Diagnostics Lab Medical Advisory Board
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 29 Nov 2010
Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2010
Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 27 Apr 2010
CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Apr 2010
Recordati Signs Co-Marketing Agreement With Esteve in Spain for Pitavastatin
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Aug 2009
FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 9 Jun 2009
Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Sep 2008
Brigham and Women's Hospital and Celera Publish Results Demonstrating That Carriers of a Variant of the LPA Gene Have More Than Two-Fold Higher Risk of Major Cardiovascular Events and That This Risk is Eliminated by Aspirin Therapy
Cardiology
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 21 Jul 2008
Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Jul 2008
TREDAPTIVE(TM) (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 May 2008
Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Reported Significantly Less Flushing Than Patients Treated with Niaspan(TM) in Phase III Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 15 Jan 2008
First Head to Head Study Comparing Crestor(TM) and Lipitor(R) Effects on the Treatment of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 20 Nov 2007
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Nov 2007
Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2007
Genzyme Launches Cholestagel(R) in Europe
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2007
Merck's Investigational Lipid-Modifier, CORDAPTIVE(TM) (ER niacin/laropiprant), Positively Affected Key Lipid Parameters With Less Flushing, In Data from Phase III Study
Biopharmaceuticals Drug Delivery Cardiology
 HSMN NewsFeed - 31 Aug 2007
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Biopharmaceuticals
 HSMN NewsFeed - 29 Aug 2007
Merck Announces FDA Acceptance of NDA for CORDAPTIVE(TM) (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
Biopharmaceuticals
 HSMN NewsFeed - 23 Jun 2007
New Study Demonstrates Colesevelam HCl Lowers Both A1C and LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Apr 2007
Abbott Submits New Drug Application for Combination Niaspan(R)/Simvastatin Tablet
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2007
Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Mar 2007
First Study to Show Positive Benefit on Atherosclerosis for People With Early Signs of Diseased Arteries
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Feb 2007
PPD Licenses Statin from Ranbaxy Laboratories
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Jan 2007
New England Journal of Medicine Reports Aegerion's Lead Compound Reduces LDL By 51% in Patients With a Severe Form of Hypercholesterolemia
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 Dec 2006
Reliant Pharmaceuticals Submits New Data to FDA Supporting Use of Omacor(R) (Omega-3-Acid Ethyl Esters) With a Statin to Reduce High Triglycerides
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
Merck's Investigational MK-0524 Significantly Reduced Flushing Caused By Extended-Release Niacin in Phase II Study
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Oct 2006
IMPAX Receives FDA Approval for Generic Version of Colestid(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 22 Oct 2006
Study Results Found Low-Dose Orlistat (60 mg) Demonstrates Significant Reduction in LDL Cholesterol While Providing Weight Loss for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
Merck Revises Regulatory Filing Timeline for MK-0524B, an Investigational Fixed-Dose Combination of MK-0524A and Simvastatin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Sep 2006
Celera Identifies FCAR Genetic Polymorphism Associated with Increased Risk for Myocardial Infarction
Cardiology
 HSMN NewsFeed - 14 Sep 2006
ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 6 Sep 2006
New EXPLORER Results Show Patients Achieved Dramatic Reductions in C-Reactive Protein And LDL-C Levels With CRESTOR Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Jul 2006
Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Jun 2006
New Data Published in an American Heart Association Journal Shows That Lipoprotein-Associated Phospholipase A2 Independently Adds to the Diagnostic Accuracy of Traditional Risk Assessment for Future Cardiovascular Events
Diagnostics Cardiology
 HSMN NewsFeed - 23 Jun 2006
Dr. Reddy's launches authorized generic versions of Proscar(R) and Zocor(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2006
Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New Analysis Shows
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 87

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 87 additional stories matching:
LDL-C
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.